Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication July 31, 2019
- Accepted for publication September 20, 2019
- Published online May 1, 2020.
Article Versions
- previous version (October 10, 2019 - 14:15).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Clemens Kratochwil1,
- Frederik L. Giesel1,
- Claus-Peter Heussel2,
- Daniel Kazdal3,
- Volker Endris3,
- Cathleen Nientiedt4,5,
- Frank Bruchertseifer6,
- Maximilian Kippenberger5,
- Hendrik Rathke1,
- Jonas Leichsenring3,
- Markus Hohenfellner7,
- Alfred Morgenstern6,
- Uwe Haberkorn1,8,
- Stefan Duensing*,5,7 and
- Albrecht Stenzinger*,3
- 1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
- 2Thorax Centre, Department of Interventional and Diagnostic Radiology, Heidelberg University Hospital, Heidelberg, Germany
- 3Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany
- 4Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany
- 5Section of Molecular Urooncology, Department of Urology, Heidelberg University Hospital, Heidelberg, Germany
- 6Directorate for Nuclear Safety and Security, European Commission–Joint Research Centre, Karlsruhe, Germany
- 7Department of Urology, Heidelberg University Hospital, Heidelberg, Germany; and
- 8Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
- For correspondence or reprints contact: Clemens Kratochwil, Department of Nuclear Medicine, University Hospital Heidelberg, INF 400, Heidelberg, BW 69120, Germany. E-mail: clemens.kratochwil{at}med.uni-heidelberg.de
↵* Contributed equally to this work.
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis
- Pharmacogenomics in Radionuclide Therapy: Impact on Response to Theranostics
- Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer
- The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer